Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

• Published in: Nature medicine Vol. 21; no. 6; pp. 560 - 562
• Main Authors: Thress, Kenneth S, Paweletz, Cloud P, Felip, Enriqueta, Cho, Byoung Chul, Stetson, Daniel, Dougherty, Brian, Lai, Zhongwu, Markovets, Aleksandra, Vivancos, Ana, Kuang, Yanan, Ercan, Dalia, Matthews, Sarah E, Cantarini, Mireille, Barrett, J Carl, Jänne, Pasi A, Oxnard, Geoffrey R
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.06.2015; Nature Publishing Group
• Subjects: 45/23; 45/77; 692/308/575; 692/699/67/1612/1350; Acrylamides - administration & dosage; Adult; Aged; Aniline Compounds - administration & dosage; Biomedicine; brief-communication; Cancer Research; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Deoxyribonucleic acid; DNA; Drug resistance; Drug Resistance, Neoplasm; Drug therapy; ErbB Receptors - genetics; Female; Genetic aspects; High-Throughput Nucleotide Sequencing; Humans; Infectious Diseases; Lung cancer; Lung cancer, Non-small cell; Male; Metabolic Diseases; Middle Aged; Molecular Medicine; Mutation; Neurosciences; Plasma; Risk factors; Tumors; United States; South Korea
• ISSN: 1078-8956; 1546-170X
• DOI: 10.1038/nm.3854

A mutation conferring resistance to novel irreversible EGFR inhibitors is identified in cell-free plasma DNA from lung cancer patients. Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291. We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291. We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects. All were positive for the T790M mutation before treatment, but upon developing AZD9291 resistance three molecular subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation. Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.